Monday, June 8, 2026

Latest

Hexo: Canaccord Lowers Price Target Following Poor Execution

On Monday, Hexo Corp (TSX: HEXO) (NYSE: HEXO) reported their fiscal third-quarter estimates which missed consensus estimates significantly. HEXO reported revenues of $22.7 million, a measly 2% increase year over year and a ~31% decrease quarter over quarter. Gross profit came in at $4.38 million, and had the same fate as revenue, cratering 61.3% quarter over quarter.

Many analysts have come out and lowered their targets and ratings on the company. ATB, Alliance, CIBC, Stifel-GMP, and Canaccord lowered their 12-month price targets bringing the consensus 12-month price target to C$8.43, down from C$9.47 from before the release. The company has 12 analysts covering the stock with three analysts having buy ratings, eight analysts have hold ratings and one analyst has a strong sell rating. The street high comes from Alliance Global with a C$12 price target while the lowest comes in at C$5.97.

In Canaccord’s note, they lowered their 12-month price target to C$7.00 from C$9.00 and reiterated their hold rating on the name. Matt Bottomley says that this quarter “represented a step back with respect to the company’s execution in its core legacy business,” even though the recent M&A puts the company in a top-three market share position.

For this quarter, the company reported revenues $10 million lower than Canaccord’s estimates. This is concerning to Bottomley due to the company seeing sales in its core market drop by $5.2 million and the company having issues with its production of hash products during the quarter. BUT the company boasted a leading market share of 46% in beverages!

Bottomley warns that the volatility in LP’s revenue might continue as “the saturated Canadian cannabis landscape continues to evolve,” and believes that this is a very high risk to the LP’s fundamentals.

Below you can see Canaccord’s updated full-year 2021 and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Gold Trade Is Shifting From Margins to Growth | Geordie Mark – Blue Jay Gold

CopAur Minerals – This PEA Has A Mine Life of What?!

Ontario’s Fast Track to Silver Production Is Starting to Matter | Frank Basa – Nord Precious Metals

Recommended

Antimony Resources Trenching at Bald Hill Averages 19.5% Antimony, Peaks at 44.2%

Amid CBS Shuffle, Is Joe Rogan Replacing Anderson Cooper On 60 Minutes?

Related News

BMO Lowers Price Target On Equinox Gold Following Production Suspension At RDM Mine

Earlier this month Equinox Gold (TSX: EQX) revealed that they are temporarily suspending operations at...

Monday, May 30, 2022, 10:58:00 AM

Meta Platforms: Canaccord Drops Price Target To $330

Last week Meta Platforms (NASDAQ: FB) reported its first quarter financial results. The company saw...

Sunday, May 8, 2022, 11:14:00 AM

Xebec Adsorption: Canaccord Cuts Target On “Significantly Weaker Than Expected” Quarter

Last week Xebec Adsorption (TSX: XBC) announced its first quarter financial results. The company reported...

Monday, May 16, 2022, 04:28:00 PM

Nike: BMO Lowers Price Target To $170 Following Q1 Results

Earlier this week, Nike Inc (NYSE: NIKE) reported its fiscal first quarter of 2022. The...

Friday, October 1, 2021, 04:45:00 PM

Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target

Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company...

Tuesday, August 18, 2020, 01:46:28 PM